Luye Pharma Group Ltd.
Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02603770
- Locations
- 🇺🇸
NRC Research Institute, Orange, California, United States
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
- Conditions
- Major Depressive Disorder, Recurrent, Unspecified
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT02271412
- Locations
- 🇺🇸
PRA Health Sciences, Marlton, New Jersey, United States
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02186769
- Locations
- 🇺🇸
Neuropsychiatric Research Center of Orange County, Orange County, California, United States
🇺🇸Community Clinical Research Inc, Austin, Texas, United States
Bioavailability of LY03004 and Risperdal® Consta®
- Conditions
- Schizoaffective DisorderSchizophrenia
- Interventions
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT02091388
- Locations
- 🇺🇸
Neuropsychiatric Research Center of Orange County, Orange, California, United States
🇺🇸Collaborative Neuroscience Network LLC, Long Beach, California, United States
🇺🇸Compass Research, Leesburg, Florida, United States
Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT02055274
- Locations
- 🇺🇸
Collaborative Neuroscience Network LLC, Long Beach, California, United States
🇺🇸West Georgia Sleep Disorders Center and Neurology Associates, Douglasville, Georgia, United States
🇺🇸Quest Research Institute, Bingham Farms, Michigan, United States
Safety, Tolerability and Pharmacokinetics Study of LY03005
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT02055300
- Locations
- 🇺🇸
Medpace, Cincinnati, Ohio, United States
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02055287
- Locations
- 🇺🇸
Neuropsychiatric Research Center of Orange County, Orange, California, United States
🇺🇸Community Clinical Research Inc, Austin, Texas, United States